Myocardial Reperfusion Injury

Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm.

Also Known As:

Networked: 604 relevant articles (44 outcomes, 97 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Ischemia
2.	ST Elevation Myocardial Infarction
3.	Reperfusion Injury
4.	Infarction (Infarctions)
5.	Myocardial Infarction

Experts

1.	Badalzadeh, Reza: 8 articles (03/2022 - 12/2012)
2.	Das, Dipak K: 7 articles (09/2008 - 02/2006)
3.	Yellon, Derek M: 6 articles (03/2016 - 09/2003)
4.	Sellke, Frank W: 5 articles (01/2016 - 10/2002)
5.	Montecucco, Fabrizio: 4 articles (04/2016 - 08/2009)
6.	Hausenloy, Derek J: 4 articles (03/2016 - 03/2009)
7.	Lefer, David J: 4 articles (01/2016 - 01/2003)
8.	Gao, Erhe: 4 articles (03/2015 - 05/2002)
9.	Gao, Feng: 4 articles (02/2015 - 02/2002)
10.	Braunersreuther, Vincent: 4 articles (11/2013 - 04/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myocardial Reperfusion Injury:

1.	Superoxide DismutaseIBA 01/01/1993 - "The efficacy of superoxide dismutase administered using synchronized coronary venous retroperfusion (SRP) on the extent of myocardial reperfusion injury was studied. " 01/01/1992 - "The efficacy of recombinant human extracellular-superoxide dismutase type C (EC-SOD C) on myocardial reperfusion injury was explored in hypothermically arrested rat hearts, as was its site of action. " 01/01/1992 - "Effects of recombinant human extracellular-superoxide dismutase type C on myocardial reperfusion injury in isolated cold-arrested rat hearts." 12/01/1990 - "We also observed the protective effect of superoxide dismutase (SOD) on myocardial ischemic-reperfusion injury. " 10/01/1995 - "Interleukin 1 alpha-induced expression of manganous superoxide dismutase reduces myocardial reperfusion injury in the rat."
2.	AntioxidantsIBA 10/01/1991 - "This study examined the efficacy of this antioxidant and redox agent in attenuating myocardial reperfusion injury. " 09/20/2006 - "The present study investigates the cardioprotective effects of Hibiscus rosa sinensis in myocardial ischemic reperfusion injury, particularly in terms of its antioxidant effects. " 10/01/2008 - "Several antioxidants have been found to have conflicting results in attenuating myocardial reperfusion injury. " 01/01/1987 - "The assumption is supported that radical-induced LPO is of pathogenetic relevance during myocardial reperfusion injury for which antioxidants could be of therapeutic advantage." 01/01/2022 - "Pharmacological Basis for Abrogating Myocardial Reperfusion Injury Through a Multi-Target Combined Antioxidant Therapy."
3.	Free RadicalsIBA 11/22/2015 - "[The role of free radicals in the myocardial reperfusion injuries and in the development of endogenous adaptation]." 12/01/2004 - "Numerous investigators have reported the mechanisms underlying myocardial reperfusion injury such as generation of free radicals, disturbance in the intracellular ion homeostasis, and lack of energy for contraction. " 03/01/2003 - "Free radicals have been implicated in myocardial reperfusion injury. " 07/01/1994 - "1. Myocardial 'reperfusion injury' has been partly attributed to the production of free radicals which are cytotoxic towards cells. " 07/01/1994 - "Free radicals and lipid peroxidation have been suggested to play an important role in the pathophysiology of myocardial reperfusion injury. "
4.	Adenosine (Adenocard)FDA LinkGeneric 02/01/1992 - "To determine the efficacy of very low doses of adenosine on myocardial reperfusion injury and whether its effect is receptor mediated, 78 rabbits underwent 30 minutes of left circumflex artery occlusion and 48 hours of reperfusion. " 11/01/1991 - "The purpose of this study was to investigate the effects of various doses of adenosine administered intravenously on myocardial reperfusion injury in a model with poor collateral blood flow. " 01/01/2015 - "Adenosine 2B Receptor Activation Reduces Myocardial Reperfusion Injury by Promoting Anti-Inflammatory Macrophages Differentiation via PI3K/Akt Pathway." 07/01/2004 - "Myocardial reperfusion injury was present in 19% of patients receiving adenosine versus 35% of control patients (p = 0.004). " 09/01/2003 - "Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2."
5.	Cyclosporine (Ciclosporin)FDA LinkGeneric 04/01/2016 - "Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS Trial - pharmacological reasons for failure." 08/01/2014 - "Closing the pore on reperfusion injury: myocardial protection with cyclosporine." 04/01/2012 - "The role of cyclosporine in the treatment of myocardial reperfusion injury." 05/01/2010 - "Cyclosporine A (CsA) limits myocardial reperfusion injury and preserves mitochondrial integrity, but its influence on mitochondrial function has not been described in vivo. " 10/01/1993 - "On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury."
6.	Oxygen (Dioxygen)IBA 12/19/2017 - "Hyperbaric oxygen protects against myocardial reperfusion injury via the inhibition of inflammation and the modulation of autophagy." 12/01/1990 - "Many studies have provided indirect evidence that there is a relationship between oxygen free radical and myocardial ischemic-reperfusion injury. " 01/01/2021 - "However, reestablishment of blood flow and oxygen levels to the infarcted area are also associated with an accumulation of reactive oxygen species (ROS), leading to oxidative damage and cardiomyocyte death, a phenomenon termed myocardial reperfusion injury. " 08/07/2000 - "The common inducers of apoptosis include oxygen free radicals/oxidative stress and Ca(2+) which are also implicated in the pathogenesis of myocardial ischemic reperfusion injury. " 12/01/1998 - "A specific action against myocardial reperfusion injury of the oxygen paradox type was recently characterized for halothane after anoxic perfusion in isolated rat hearts and isolated cardiomyocytes. "
7.	IronIBA 02/01/1994 - "Exogenous intracellular, but not extracellular, iron augments myocardial reperfusion injury." 03/01/2003 - "In addition to these effects, important in atherosclerosis, ample experimental evidence suggests a role of iron in myocardial reperfusion injury. " 12/01/1994 - "The aim of this study was to determine whether a diet containing iron to a concentration of the recommended upper limit alters the degree of myocardial ischemic/reperfusion injury on rats and whether simultaneous antioxidant supplementation had any effect. " 01/01/2019 - "Myocardial reperfusion injury is characterized by iron deposition as well as reactive oxygen species production. " 05/01/2002 - "Time window of nitroxide effect on myocardial ischemic-reperfusion injury potentiated by iron."
8.	Deferoxamine (Desferal)FDA LinkGeneric 01/01/1989 - "Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury." 05/01/2012 - "Combined intravenous treatment with ascorbic acid and desferrioxamine to reduce myocardial reperfusion injury in an experimental model resembling the clinical setting of primary PCI." 11/01/1996 - "Although previous studies have investigated the protective effect of iron chelators including deferoxamine (DFX) in myocardial reperfusion injury, there is little information regarding the role of iron chelation during oxidative stress produced by H2O2 on the heart. " 10/01/1987 - "The present study was designed to test the hypothesis that myocardial reperfusion injury might be reduced by administration of the iron chelator deferoxamine at the time of reflow, most likely by preventing hydroxyl radical formation. " 07/01/1987 - "A Langendorff isolated rat heart preparation was used to determine the effect of oxypurinol, a xanthine oxidase inhibitor, and deferoxamine, an iron binding agent, on the extent of myocardial reperfusion injury after 60 minutes of ischaemia. "
9.	Peptides (Polypeptides)IBA 09/30/2013 - "Achyranthes bidentata polypeptides reduces oxidative stress and exerts protective effects against myocardial ischemic/reperfusion injury in rats." 01/01/2020 - "A novel therapeutic peptide targeting myocardial reperfusion injury." 06/01/2015 - "Inhibition of the TREM-1 pathway by a synthetic peptide limited myocardial reperfusion injury in a clinically relevant porcine model of AMI." 01/10/2023 - "Intravenous Transplantation of an Ischemic-specific Peptide-TPP-mitochondrial Compound Alleviates Myocardial Ischemic Reperfusion Injury." 01/01/2017 - "The peptide has been shown to be effective in halting or reversing many of the adverse effects including fibrosis in animal models of cardiovascular disease including ischaemia/reperfusion injury, myocardial infarction, hypertensive heart disease and cardiomyopathy. "
10.	Exenatide (Byetta)FDA Link 07/01/2017 - "These results suggest that, for the therapy of myocardial reperfusion injury the combined administration of exenatide and cyclosporine A or parstatin 1-26 is more effective than monotherapies and may provide advantageous clinical outcome." 07/01/2017 - "Exenatide and cyclosporine A have been shown to moderately protect against myocardial reperfusion injury leading to reduction of infarct size in patients. " 04/21/2016 - "To further reduce infarct size and thus ameliorate clinical outcome, the focus has also shifted towards early detection of MI with high-sensitive troponin assays, imaging, cardioprotection against pathophysiological targets of myocardial reperfusion injury with mechanical (ischaemic post-conditioning, remote ischaemic pre-conditioning, therapeutic hypothermia, and hypoxemia) and newer pharmacological interventions (atrial natriuretic peptide, cyclosporine A, and exenatide). " 03/26/2014 - "An improved understanding of the pathophysiological mechanisms underlying reperfusion injury has resulted in the identification of several promising pharmacological (cyclosporin-A, exenatide, glucose-insulin-potassium, atrial natriuretic peptide, adenosine, abciximab, erythropoietin, metoprolol and melatonin) therapeutic strategies for reducing the severity of myocardial reperfusion injury. "

Therapies and Procedures

1.	Therapeutics 04/01/2010 - "To determine whether the efficacy of FX06 was dependent upon the timing of reperfusion therapy or the presence of collaterals in the Efficacy of FX06 in the prevention of myocardial reperfusion injury (F.I.R.E.) trial. " 01/01/2014 - "This overview will discuss these trials, the progression in attenuating myocardial reperfusion injury, promising therapies, and future perspectives. " 01/01/2023 - "Nanomedicine-Based Therapeutics for Myocardial Ischemic/Reperfusion Injury." 01/01/2021 - "However, reperfusion may cause additional damage, known as myocardial reperfusion injury, for which there is still no effective therapy. " 01/01/2021 - "Myocardial reperfusion injury is the result of several complex nonlinear phenomena, and for a therapy to be effective, it should act on multiple targets involved in this injury. "
2.	Induced Heart Arrest (Cardioplegia) 11/01/2013 - "We performed a two-level search to identify randomized, controlled trials concerning the effects of leukocyte-depleted blood cardioplegia on myocardial reperfusion injury. " 09/01/2020 - "To mitigate the risk to myocardial reperfusion injury, appropriate cardioplegia volume and distribution and well-defined surgical repair processes are equally important. " 11/01/2013 - "Leukocyte-depleted blood cardioplegia may reduce myocardial reperfusion injury in the early postoperative period, but there has been no evidence to support the clinically significant difference. " 11/01/2013 - "Blood cardioplegia in cardiac surgery contains leukocytes, which causes the inflammatory reaction and promotes myocardial reperfusion injury. " 11/01/2013 - "Does leukocyte-depleted blood cardioplegia reduce myocardial reperfusion injury in cardiac surgery? "
3.	Ischemic Postconditioning 12/01/2010 - "DHI and ischemic postconditioning show a synergistic cardioprotection on myocardial reperfusion injury in minipigs." 01/01/2022 - "Guanxinning Injection Combined With Ischemic Postconditioning Attenuate Myocardial Ischemic Reperfusion Injury in Chronic Renal Failure Rats by Modulating Mitochondrial Dynamics." 03/01/2022 - "Alpha-lipoic acid preconditioning plus ischemic postconditioning provides additional protection against myocardial reperfusion injury of diabetic rats: modulation of autophagy and mitochondrial function." 07/01/2015 - "The aim of the present study was to examine whether ischemic postconditioning (PostC) might activate SIRT3 and consequently prevent lethal myocardial reperfusion injury through a deacetylation of CyPD. " 06/01/2018 - "Combination of Vildagliptin and Ischemic Postconditioning in Diabetic Hearts as a Working Strategy to Reduce Myocardial Reperfusion Injury by Restoring Mitochondrial Function and Autophagic Activity."
4.	Cardiopulmonary Bypass (Heart-Lung Bypass) 09/01/2005 - "The purpose of this study is to investigate the effect of cardiopulmonary bypass (CPB) temperature on myocardial reperfusion injury, oxidative stress, and inflammatory response in pediatric open heart surgery. " 01/01/2021 - "Early Identification of Myocardial Reperfusion Injury After Cardiopulmonary Bypass: Toward the Final Frontier of Congenital Heart Surgery." 02/01/2018 - "Classic cardiac surgery, determined through the function of cardiopulmonary bypass machine and myocardial cardioplegic arrest, represents the most controlled scenario for cardiomyocyte homeostatic disturbances due to systemic inflammatory response and myocardial reperfusion injury. " 06/21/2013 - "Myocardial ischemic reperfusion injury with cardiopulmonary bypass results in declining level of mir-499 expression in left ventricle myocardium of canines, suggesting mir-499 would be a potential therapeutic target in cardiac protection during open heart surgery." 01/01/1996 - "Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations."
5.	Percutaneous Coronary Intervention 09/01/2020 - "With the widespread use of coronary artery bypass grafting and percutaneous coronary intervention(PCI), myocardial reperfusion injury is a major clinical problem. " 07/15/2009 - "Recent proof-of-concept clinical trials support the idea that lethal myocardial reperfusion injury is also of significant importance in patients with ongoing AMI, and that targeting mitochondrial permeability transition by either percutaneous coronary intervention postconditioning or CsA can reduce infarct size and improve the recovery of contractile function after reperfusion. " 01/01/2021 - "Myocardial reperfusion injury-triggered by an inevitable inflammatory response after reperfusion-may undo a considerable part of the myocardial salvage achieved through timely percutaneous coronary intervention in patients with acute myocardial infarction. " 04/01/2009 - "Aims Successful epicardial reperfusion with primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) can paradoxically evoke myocardial reperfusion injury, which may be signalled by temporally associated ventricular arrhythmias (VAs). " 01/01/2022 - "Identifying novel mediators of lethal myocardial reperfusion injury that can be targeted during primary percutaneous coronary intervention (PPCI) is key to limiting the progression of patients with ST-elevation myocardial infarction (STEMI) to heart failure. "